Clinico-Radiological-Pathologic Profile and Outcomes of Lung Transplant in Post–COVID-19 Phenotype: A Single Center Experience

Shah, Unmil; Rahulan, V.; Srinivas, R.; Kumar, Sunil; Mohandas, K. Anoop; Kori, Santosh; Panda, Sushant; Singh, Vivek; Kumar, Pradeep; Prasanna, G.; Rao, I. Satish; Kalle, Abhiram; Manish, D.; John, Prem Anand; Mahesh, B.N.; Dutta, Parikshit; Attawar, Sandeep

doi:10.1016/j.transproceed.2022.03.007

Cited by 1 publication

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 The development of cytomegalovirus (CMV) disease after recovery from the SARS-CoV-2 infection has been reported. [17][18][19][20][21][22] However, there is no large and comprehensive study to investigate the CMV disease after the acute COVID-19 episode. Additionally, the relationship between subsequent CMV disease and COVID-19 remains unclear because of limited evidence based on mostly case reports.…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, the relationship between subsequent CMV disease and COVID-19 remains unclear because of limited evidence based on mostly case reports. [17][18][19][20][21][22] Therefore, the objective of this study was to assess the incidence of CMV disease among individuals who have survived COVID-19, utilizing real-world data for analysis. 23,24 The study protocol was approved by the Institutional Review Board of the Chi Mei Medical Center (no.…”

Section: Introductionmentioning

confidence: 99%

“…COVID‐19 patients are likely to experience an augmented susceptibility to infection, potentially attributable to a combination effect of virus‐induced and drug‐induced immunosuppression 16 . The development of cytomegalovirus (CMV) disease after recovery from the SARS‐CoV‐2 infection has been reported 17–22 . However, there is no large and comprehensive study to investigate the CMV disease after the acute COVID‐19 episode.…”

Section: Introductionmentioning

confidence: 99%

“…However, there is no large and comprehensive study to investigate the CMV disease after the acute COVID‐19 episode. Additionally, the relationship between subsequent CMV disease and COVID‐19 remains unclear because of limited evidence based on mostly case reports 17–22 . Therefore, the objective of this study was to assess the incidence of CMV disease among individuals who have survived COVID‐19, utilizing real‐world data for analysis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Risk of cytomegalovirus diseases among coronavirus disease survivors: A retrospective cohort study

Zhang,

Tsai,

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

This study was aimed at investigating the risk of cytomegalovirus (CMV) disease among coronavirus disease 2019 (COVID‐19) survivors. In this retrospective cohort study, we used the TriNetX research network to identify adults with and without COVID‐19 between January 1, 2022 and December 31, 2022. Propensity score matching was used to match the patients with and without COVID‐19. The primary outcome was the risk of CMV disease during the 90‐day follow‐up period. Two matched cohorts comprising 2 501 634 patients with balanced baseline characteristics were created using propensity score matching. During the follow‐up period, patients with COVID‐19 had a higher risk of CMV disease than those without COVID‐19 (hazard ratio [HR], 2.55; 95% confidence interval: 2.01–3.23). The higher risk of CMV disease in the COVID‐19 cohort compared with that of the non‐COVID‐19 cohort remained unchanged in the subgroup analyses by sex (men: HR, 1.85 [1.38–2.47]; women: HR, 2.31 [1.63–3.27]), age (18–64 years: HR, 2.21 [1.71–2.85]; ≥65 years: HR, 1.97 [1.20–3.25]), obesity (HR, 1.54 [1.04–2.30]), diabetes mellitus (HR, 1.50 [1.08–2.08]), cancer (HR, 3.10 [1.95–4.92]), glucocorticoid use (HR, 3.14 [2.45–4.02]), transplantation (HR, 1.38 [1.08–1.77]), and unvaccinated status (HR, 2.37 [1.82–3.08]). In conclusion, COVID‐19 can increase the risk of CMV disease. Clinicians should be aware of the risk of CMV disease in patients with COVID‐19.

show abstract